Spinal Muscular Atrophy (SMA) - Pipeline Review, H2 2018 - ResearchAndMarkets.com

September 19, 2018

DUBLIN--(BUSINESS WIRE)--Sep 19, 2018--The “Spinal Muscular Atrophy (SMA) - Pipeline Review, H2 2018” drug pipelines has been added to ResearchAndMarkets.com’s offering.

Spinal Muscular Atrophy (SMA) - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Spinal Muscular Atrophy (SMA) (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.

The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Spinal Muscular Atrophy (SMA) (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Spinal Muscular Atrophy (SMA) and features dormant and discontinued projects.

The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 4, 2, 4, 20 and 7 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 7 and 3 molecules, respectively.

Spinal Muscular Atrophy (SMA) (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Companies Featured

AndroScience Corp AveXis Inc Biogen Inc BioMarin Pharmaceutical Inc Cytokinetics Inc Exicure Inc F. Hoffmann-La Roche Ltd Genethon SA Ionis Pharmaceuticals Inc Kowa Co Ltd Neurodyn Life Sciences Inc Neurotune AG Novartis AG Ono Pharmaceutical Co Ltd Paratek Pharmaceuticals Inc Recursion Pharmaceuticals Inc Sarepta Therapeutics Inc Scholar Rock Inc Spotlight Innovation Inc Vybion Inc

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/h8jn89/spinal_muscular?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20180919005322/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Manager


For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Central Nervous System Drugs



SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 09/19/2018 06:39 AM/DISC: 09/19/2018 06:39 AM


Update hourly